Alimera Sciences Announces New PDUFA Date For ILUVIEN®

            Alimera Sciences Announces New PDUFA Date For ILUVIEN®

PDUFA goal date set for October 17, 2013

PR Newswire

ATLANTA, May 1, 2013

ATLANTA, May 1, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that its recent resubmission of the New Drug Application (NDA)
for ILUVIEN^® has been acknowledged as received by the U.S. Food and Drug
Administration (FDA) as a complete class 2 response to the FDA's November 2011
letter and that a new Prescription Drug User Fee Act (PDUFA) goal date of
October 17, 2013 has been established.

In the resubmission, Alimera responded to questions raised in the FDA's letter
and provided additional analyses as well as new information to support that
ILUVIEN is safe and effective in the treatment of patients with chronic
diabetic macular edema (DME).

Using data from Alimera's two previously completed pivotal Phase 3 clinical
trials (collectively the FAME™ Study), the resubmission focused on the safety
aspects of ILUVIEN and the subgroup population of patients with chronic DME,
the same subgroup for which marketing approval for ILUVIEN has been granted in
six countries in the European Union. Additionally, data was submitted from the
completed physician utilization study for the ILUVIEN applicator and from a
special reading center assessment of photographs of the fundus, or interior
surface of the eye, which were collected during the FAME™ Study.

At month 36, the treatment effect for the chronic DME subgroup (i.e. the
difference in the proportion of 15 Early Treatment Diabetic Retinopathy Study
(ETDRS) eye chart letter responders between ILUVIEN and the sham control) was
more than twice that seen for the overall population. Given that the risks
associated with the chronic DME subgroup are similar to the risks in the
overall population, Alimera believes that the benefit to risk for this
subgroup is optimized with ILUVIEN treatment.

"We believe this FDA resubmission package includes important new information
that demonstrates the safety and efficacy of ILUVIEN for patients suffering
from chronic DME," said Dan Myers, Alimera's president and chief executive
officer. "We believe a clearer positioning now exists for ILUVIEN in the
treatment of patients with chronic DME, since a first line pharmacotherapy for
DME was approved by the FDA last year. We look forward to the FDA's response
to our New Drug Application. In the meantime, we continue to move forward with
our ILUVIEN commercial launch plans in Europe."

About ILUVIEN^®

ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in
applicator) is a sustained release intravitreal implant used to treat vision
impairment associated with chronic DME considered insufficiently responsive to
available therapies. Each ILUVIEN implant provides a therapeutic effect of up
to 36 months by delivering sustained sub-microgram levels of fluocinolone
acetonide (FAc). ILUVIEN is injected in the back of the patient's eye to a
position that takes advantage of the eye's natural fluid dynamics. The
applicator employs a 25-gauge needle, which allows for a self-sealing wound.
In the two Phase 3 pivotal clinical trials (collectively known as the FAME™
Study) for ILUVIEN conducted by Alimera, the most frequently reported adverse
drug reactions included cataract operation, cataract and increased ocular
pressure.

In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to
seven European countries via the Decentralized Procedure (DCP) with the
Medicines and Healthcare products Regulatory Agency of the U.K. serving as the
Reference Member State (RMS). The MAA included data from the FAME Study, which
involved 956 patients in sites across the United States, Canada, Europe and
India to assess the efficacy and safety of ILUVIEN for the treatment of DME.
At the end of the DCP, a consensus was reached by the RMS and the other six
countries that the MAA for ILUVIEN was approvable. To date, six of the seven
countries, Austria, the United Kingdom, Portugal, France, Germany and Spain
have granted national licenses for ILUVIEN, which is now available in the
United Kingdom. ILUVIEN has not been approved by the FDA.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a
non-proprietary corticosteroid with demonstrated efficacy in the treatment of
ocular disease.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, the regulatory status of ILUVIEN in the United States and
Alimera's commercial launch plans in Europe. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change any of
them, and could cause actual results to differ materially from those projected
in its forward-looking statements. Meaningful factors which could cause actual
results to differ include, but are not limited to, delay in or failure to
obtain FDA approval of ILUVIEN, as well as other factors discussed in the
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Alimera's Annual Report on
Form 10-K for the year ended December 31, 2012, which is on file with the
Securities and Exchange Commission (SEC) and available on the SEC's website at
www.sec.gov. In addition to the risks described above and in Alimera's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the SEC, other unknown or unpredictable factors
also could affect Alimera's results. There can be no assurance that the actual
results or developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected consequences to, or
effects on, Alimera. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or otherwise



For press inquiries:
                                For investor inquiries:
Katie Brazel, Fleishman-Hillard
                                John Mills, ICR
for Alimera Sciences
                                for Alimera Sciences
404-739-0150                    310-954-1105
                                 John.Mills@ICRINC.com
Katie.Brazel@fleishman.com

SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com
 
Press spacebar to pause and continue. Press esc to stop.